<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01800968</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00042633</org_study_id>
    <secondary_id>5U10HL084904-09</secondary_id>
    <nct_id>NCT01800968</nct_id>
  </id_info>
  <brief_title>Functional Impact of GLP-1 for Heart Failure Treatment (FIGHT)</brief_title>
  <acronym>FIGHT</acronym>
  <official_title>Functional Impact of GLP-1 for Heart Failure Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to test the hypothesis that, compared with placebo, therapy with
      Subcutaneous (SQ) GLP-1 agonist in the post-Acute Heart Failure Syndrome (AHFS) discharge
      period will be associated with greater clinical stability at six months as assessed by a
      composite clinical endpoint.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hospitalization for AHFS identifies individuals at increased risk of death and
      re-hospitalization following discharge. This increased risk justifies intervention with novel
      therapy during the vulnerable post-discharge period to enhance clinical stability and prevent
      early HF mortality and readmissions.

      As heart failure (HF) progresses, impairments in metabolism render the heart substrate
      constrained, limiting cardiac metabolism. Glucagon-like peptide-1 (GLP-1) is a naturally
      occurring incretin peptide that enhances cellular glucose uptake by stimulating insulin
      secretion and insulin sensitivity in target tissues. Preclinical and early-phase clinical
      data support GLP-1 as an effective therapy for advanced HF while use of GLP-1 receptor
      agonists in large numbers of patients with diabetes reveal a good safety profile and
      reductions in adverse cardiac outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Global Ranking of Predefined Events</measure>
    <time_frame>Randomization to 180 days</time_frame>
    <description>A rank score based on time to death, time to adjudicated heart failure hospitalization, and time-averaged proportional change in NTproBNP through d180. For patients that died, the patient with the shortest time from randomization to death is assigned rank 1, the second shortest time is assigned rank 2, etc. The patient with the longest time from randomization to death is assigned rank X. For patients that did not die but had a heart failure hospitalization, the patient with the shortest time from randomization to re-admission is assigned rank X+1 and the patient with the longest time from randomization to heart failure hospitalization is assigned rank Y. For patients that did not die or have a heart failure hospitalization, increases in time-averaged proportional change in NTproBNP indicate a worse result and the largest increase is assigned rank Y+1. The patient with the largest decrease is assigned rank N, where N is the sample size.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Left Ventricular End-Diastolic Volume Index</measure>
    <time_frame>Baseline to 180 days</time_frame>
    <description>Change in Left Ventricular End-Diastolic Volume Index from baseline to 180 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Left Ventricular End-systolic Volume Index</measure>
    <time_frame>Baseline to 180 days</time_frame>
    <description>Change in left ventricular end-systolic volume index from baseline to day 180.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Left Ventricular Ejection Fraction</measure>
    <time_frame>Baseline to 180 days</time_frame>
    <description>Change in left ventricular ejection fraction from baseline to day 180</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Medial Filling Pressure</measure>
    <time_frame>Baseline to 180 days</time_frame>
    <description>Change in medial filling pressure baseline to day 180.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Lateral Filling Pressure</measure>
    <time_frame>Baseline to 180 days</time_frame>
    <description>Change in lateral filling pressure baseline to day 180.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 6 Minute Walk Distance</measure>
    <time_frame>Baseline to day 30</time_frame>
    <description>Change in 6 minute walk distance baseline to day 30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 6 Minute Walk Distance</measure>
    <time_frame>Baseline to 90 days</time_frame>
    <description>Change in 6 minute walk distance baseline to 90 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 6 Minute Walk Distance</measure>
    <time_frame>Baseline to 180 days</time_frame>
    <description>Change in 6 minute walk distance baseline to 180 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Clinical Summary Score Using the Kansas City Cardiomyopathy Questionnaire (KCCQ)</measure>
    <time_frame>Baseline to 30 days</time_frame>
    <description>Change in clinical summary score using the Kansas City Cardiomyopathy Questionnaire (KCCQ) baseline to 30 days. The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life.In the KCCQ, an overall summary score can be derived from the physical function, symptom (frequency and severity), social function and quality of life domains. For each domain, the validity, reproducibility, responsiveness and interpretability have been independently established. Each question is answered by the subject on a 6 point scale (Extremely limited, quite a bit limited, moderately limited, slightly limited, not at all limited, Limited for other reasons or did not do this activity).Scores are transformed to a range of 0-100, in which higher scores reflect better health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Clinical Summary Score Using the Kansas City Cardiomyopathy Questionnaire (KCCQ)</measure>
    <time_frame>Baseline to 90 days</time_frame>
    <description>Change in clinical summary score using the Kansas City Cardiomyopathy Questionnaire (KCCQ) baseline to 90 days.The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life.In the KCCQ, an overall summary score can be derived from the physical function, symptom (frequency and severity), social function and quality of life domains. For each domain, the validity, reproducibility, responsiveness and interpretability have been independently established. Each question is answered by the subject on a 6 point scale (Extremely limited, quite a bit limited, moderately limited, slightly limited, not at all limited, Limited for other reasons or did not do this activity).Scores are transformed to a range of 0-100, in which higher scores reflect better health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Clinical Summary Score Using the Kansas City Cardiomyopathy Questionnaire (KCCQ)</measure>
    <time_frame>Baseline to day 180</time_frame>
    <description>Change in clinical summary score using the Kansas City Cardiomyopathy Questionnaire (KCCQ) from baseline to day 180.The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life.In the KCCQ, an overall summary score can be derived from the physical function, symptom (frequency and severity), social function and quality of life domains. For each domain, the validity, reproducibility, responsiveness and interpretability have been independently established. Each question is answered by the subject on a 6 point scale (Extremely limited, quite a bit limited, moderately limited, slightly limited, not at all limited, Limited for other reasons or did not do this activity).Scores are transformed to a range of 0-100, in which higher scores reflect better health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) Overall Summary Score</measure>
    <time_frame>Baseline to 30 days</time_frame>
    <description>Kansas City Cardiomyopathy Questionnaire (KCCQ) change in overall summary score baseline to 30 days.The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life.In the KCCQ, an overall summary score can be derived from the physical function, symptom (frequency and severity), social function and quality of life domains. For each domain, the validity, reproducibility, responsiveness and interpretability have been independently established. Each question is answered by the subject on a 6 point scale (Extremely limited, quite a bit limited, moderately limited, slightly limited, not at all limited, Limited for other reasons or did not do this activity).Scores are transformed to a range of 0-100, in which higher scores reflect better health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) Overall Summary Score</measure>
    <time_frame>Baseline to 90 days</time_frame>
    <description>Kansas City Cardiomyopathy Questionnaire (KCCQ) change in overall summary score baseline to 90 days.The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life.In the KCCQ, an overall summary score can be derived from the physical function, symptom (frequency and severity), social function and quality of life domains. For each domain, the validity, reproducibility, responsiveness and interpretability have been independently established. Each question is answered by the subject on a 6 point scale (Extremely limited, quite a bit limited, moderately limited, slightly limited, not at all limited, Limited for other reasons or did not do this activity).Scores are transformed to a range of 0-100, in which higher scores reflect better health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) Overall Summary Score.</measure>
    <time_frame>Baseline to 180 days</time_frame>
    <description>Kansas City Cardiomyopathy Questionnaire (KCCQ) change in overall summary score baseline to 180 days.The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life.In the KCCQ, an overall summary score can be derived from the physical function, symptom (frequency and severity), social function and quality of life domains. For each domain, the validity, reproducibility, responsiveness and interpretability have been independently established. Each question is answered by the subject on a 6 point scale (Extremely limited, quite a bit limited, moderately limited, slightly limited, not at all limited, Limited for other reasons or did not do this activity).Scores are transformed to a range of 0-100, in which higher scores reflect better health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual Component of the Primary Endpoint- Mortality</measure>
    <time_frame>Randomization to 180 days</time_frame>
    <description>Individual component of the primary endpoint of mortality at 180 days after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual Component of the Primary Endpoint- Heart Failure Hospitalization</measure>
    <time_frame>Randomization to 180 days</time_frame>
    <description>Individual component of the primary endpoint- Heart Failure hospitalization from randomization to 180 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual Component of the Primary Endpoint- Time-averaged Proportional Change in NT-proBNP</measure>
    <time_frame>Baseline to 180 days</time_frame>
    <description>Individual component of the primary endpoint- time-averaged proportional change in NT-proBNP from baseline to 180 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Ranking of Predefined Events</measure>
    <time_frame>Baseline to 180 days</time_frame>
    <description>A rank score based on time to death, time to adjudicated heart failure hospitalization, time to emergency department visit and time-averaged proportional change in NTproBNP through d180. See Outcome Measure 1 for a general description of the outcome derivation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Acute Heart Failure</condition>
  <arm_group>
    <arm_group_label>Liraglutide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Increasing dose from 0.6mg, 1.2mg to 1.8mg SQ daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo dose increasing from 0.6mg, 1.2mg to 1.8 mg SQ daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide</intervention_name>
    <description>Active Drug</description>
    <arm_group_label>Liraglutide</arm_group_label>
    <other_name>Victoza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 years

          2. AHFS as defined by the presence of at least 1 symptom (dyspnea, orthopnea, or edema)
             AND 1 sign (rales on auscultation, peripheral edema, ascites, pulmonary vascular
             congestion on chest radiography)

          3. AHFS is the primary cause of hospitalization

          4. Prior clinical diagnosis of HF

          5. Left Ventricular Ejection Fraction(LVEF) ≤ 40% during the preceding 3 months (if no
             echo within the preceding 3 months, an LVEF ≤ 30% during the preceding three years is
             acceptable)

          6. On evidence-based medication for HF (including beta-blocker and ACE-inhibitor/ARB) or
             previously deemed intolerant

          7. Use of at least 80 mg or furosemide total daily dose (or equivalent) prior to
             admission for AHFS (a lower dose of a loop diuretic combined with a thiazide will
             count as an &quot;equivalent&quot;)

          8. Willingness to provide informed consent

        Exclusion Criteria:

          1. AHFS due to acute myocarditis or acute Myocardial Infarction

          2. Ongoing hemodynamically significant arrhythmias contributing to HF decompensation

          3. Inotrope, intra-aortic balloon pump (IABP) or other mechanical circulatory support use
             at the time of consent. Prior use will not exclude a patient.

          4. Current or planned left ventricular assist device therapy in next 180 days

          5. United Network for Organ Sharing status 1A or 1B

          6. B-type natriuretic peptide(BNP)&lt; 250 or NT-proBNP&lt;1,000 (Not required per protocol but
             if available and too low would be an exclusion; within 48 hours of consent)

          7. Hemoglobin (Hgb) &lt; 8.0 g/dl

          8. Glomerular filtration rate(GFR) &lt; 20 ml/min/1.73 m2 within 48 hours of consent

          9. Systolic blood pressure &lt; 80 mmHg at consent

         10. Resting Heart Rate &gt; 110 at consent

         11. Acute coronary syndrome within 4 weeks as defined by electrocardiographic (ECG)
             changes and biomarkers of myocardial necrosis (e.g. troponin) in an appropriate
             clinical setting (chest discomfort or anginal equivalent)

         12. Percutaneous Coronary Intervention, coronary artery bypass grafting or new
             biventricular pacing within past 4 weeks

         13. Primary hypertrophic cardiomyopathy

         14. Infiltrative cardiomyopathy

         15. Constrictive pericarditis or tamponade

         16. Complex congenital heart disease

         17. Non-cardiac pulmonary edema

         18. More than moderate aortic or mitral stenosis

         19. Intrinsic (prolapse, rheumatic) valve disease with severe mitral, aortic or tricuspid
             regurgitation

         20. Sepsis, active infection (excluding cystitis) or other comorbidity driving the HF
             decompensation

         21. Acute or chronic severe liver disease as evidenced by any of the following:
             encephalopathy, variceal bleeding, International Normalized Ration (INR) &gt; 1.7 in the
             absence of anticoagulation treatment

         22. Terminal illness (other than HF) with expected survival of less than 1 year

         23. Previous adverse reaction to the study drug

         24. Receipt of any investigational product in the previous 30 days.

         25. Enrollment or planned enrollment in another randomized therapeutic clinical trial in
             next 6 months.

         26. Inability to comply with planned study procedures

         27. Pregnancy or breastfeeding mothers

         28. Women of reproductive age not on adequate contraception

         29. History of acute or chronic pancreatitis

         30. History of symptomatic gastroparesis

         31. Familial or personal history of medullary thyroid cancer or multiple endocrine
             neoplasia type-2 (MEN2)

         32. Prior weight-loss surgery (i.e., Roux-en-Y gastric bypass) or other gastric surgery
             associated with increased endogenous GLP-1 production

         33. Prior or ongoing treatment with GLP-1 receptor agonists

         34. Ongoing treatment with dipeptidyl peptide-IV inhibitors (1 week washout required)

         35. Ongoing treatment with thiazolidinedione

         36. Oxygen-dependent chronic obstructive pulmonary disease

         37. Diabetic patients with history of 2 or more severe hypoglycemia, Diabetic
             Ketoacidosis(DKA) or hyperglycemic, hyperosmotic nonketotic coma in the preceding 12
             months.

         38. Diagnosis of Type 1 Diabetes Mellitus

        40. If diabetic, inadequate glycemic control with glucose level &gt; 300 mg/dL within 24 hours
        of randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrian Hernandez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eugene Bruanwald, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Harvard University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Christiana Care Health Services</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston VA Healtcare System</name>
      <address>
        <city>West Roxbury</city>
        <state>Massachusetts</state>
        <zip>02132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis University Hospital</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeast Regional Medical Center</name>
      <address>
        <city>Lumberton</city>
        <state>North Carolina</state>
        <zip>28538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals- Case Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metro Health System</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lancaster Heart and Stroke Foundation</name>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <zip>17603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvaina</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jefferson Medical College</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michael Debakey VA Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intermountain Medical Center</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah School of Medicine</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utah VA Medical Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Vermont- Fletcher Allen Health Care</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2013</study_first_submitted>
  <study_first_submitted_qc>February 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2013</study_first_posted>
  <results_first_submitted>September 12, 2016</results_first_submitted>
  <results_first_submitted_qc>February 14, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">February 15, 2017</results_first_posted>
  <last_update_submitted>February 14, 2017</last_update_submitted>
  <last_update_submitted_qc>February 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Liraglutide</title>
          <description>Increasing dose from 0.6mg, 1.2mg to 1.8mg subcutaneous daily.
Liraglutide: Active Drug</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo dose increasing from 0.6mg, 1.2mg to 1.8 mg subcutaneous daily.
Placebo: Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="154"/>
                <participants group_id="P2" count="146"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="118"/>
                <participants group_id="P2" count="114"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All patients randomized.</population>
      <group_list>
        <group group_id="B1">
          <title>Liraglutide</title>
          <description>Increasing dose from 0.6mg, 1.2mg to 1.8mg subcutaneous daily.
Liraglutide: Active Drug</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo dose increasing from 0.6mg, 1.2mg to 1.8 mg subcutaneous daily.
Placebo: Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="154"/>
            <count group_id="B2" value="146"/>
            <count group_id="B3" value="300"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.9" spread="12.9"/>
                    <measurement group_id="B2" value="59.6" spread="12.2"/>
                    <measurement group_id="B3" value="59.7" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                    <measurement group_id="B2" value="113"/>
                    <measurement group_id="B3" value="236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="150"/>
                    <measurement group_id="B2" value="135"/>
                    <measurement group_id="B3" value="285"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="115"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="172"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Global Ranking of Predefined Events</title>
        <description>A rank score based on time to death, time to adjudicated heart failure hospitalization, and time-averaged proportional change in NTproBNP through d180. For patients that died, the patient with the shortest time from randomization to death is assigned rank 1, the second shortest time is assigned rank 2, etc. The patient with the longest time from randomization to death is assigned rank X. For patients that did not die but had a heart failure hospitalization, the patient with the shortest time from randomization to re-admission is assigned rank X+1 and the patient with the longest time from randomization to heart failure hospitalization is assigned rank Y. For patients that did not die or have a heart failure hospitalization, increases in time-averaged proportional change in NTproBNP indicate a worse result and the largest increase is assigned rank Y+1. The patient with the largest decrease is assigned rank N, where N is the sample size.</description>
        <time_frame>Randomization to 180 days</time_frame>
        <population>All randomized subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Increasing dose from 0.6mg, 1.2mg to 1.8mg subcutaneous daily.
Liraglutide: Active Drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo dose increasing from 0.6mg, 1.2mg to 1.8 mg subcutaneous daily.
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Global Ranking of Predefined Events</title>
          <description>A rank score based on time to death, time to adjudicated heart failure hospitalization, and time-averaged proportional change in NTproBNP through d180. For patients that died, the patient with the shortest time from randomization to death is assigned rank 1, the second shortest time is assigned rank 2, etc. The patient with the longest time from randomization to death is assigned rank X. For patients that did not die but had a heart failure hospitalization, the patient with the shortest time from randomization to re-admission is assigned rank X+1 and the patient with the longest time from randomization to heart failure hospitalization is assigned rank Y. For patients that did not die or have a heart failure hospitalization, increases in time-averaged proportional change in NTproBNP indicate a worse result and the largest increase is assigned rank Y+1. The patient with the largest decrease is assigned rank N, where N is the sample size.</description>
          <population>All randomized subjects.</population>
          <units>rank</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145.5" spread="88.1"/>
                    <measurement group_id="O2" value="155.7" spread="85.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3087</p_value>
            <method>Rank score</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Left Ventricular End-Diastolic Volume Index</title>
        <description>Change in Left Ventricular End-Diastolic Volume Index from baseline to 180 days.</description>
        <time_frame>Baseline to 180 days</time_frame>
        <population>All randomized subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Increasing dose from 0.6mg, 1.2mg to 1.8mg subcutaneous daily.
Liraglutide: Active Drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo dose increasing from 0.6mg, 1.2mg to 1.8 mg subcutaneous daily.
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Left Ventricular End-Diastolic Volume Index</title>
          <description>Change in Left Ventricular End-Diastolic Volume Index from baseline to 180 days.</description>
          <population>All randomized subjects.</population>
          <units>ml per meter squared</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.37" spread="31.9"/>
                    <measurement group_id="O2" value="-2.91" spread="32.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1549</p_value>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Left Ventricular End-systolic Volume Index</title>
        <description>Change in left ventricular end-systolic volume index from baseline to day 180.</description>
        <time_frame>Baseline to 180 days</time_frame>
        <population>All randomized subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Increasing dose from 0.6mg, 1.2mg to 1.8mg subcutaneous daily.
Liraglutide: Active Drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo dose increasing from 0.6mg, 1.2mg to 1.8 mg subcutaneous daily.
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Left Ventricular End-systolic Volume Index</title>
          <description>Change in left ventricular end-systolic volume index from baseline to day 180.</description>
          <population>All randomized subjects.</population>
          <units>ml per meter squared</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.16" spread="26.2"/>
                    <measurement group_id="O2" value="-3.47" spread="26.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1932</p_value>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Left Ventricular Ejection Fraction</title>
        <description>Change in left ventricular ejection fraction from baseline to day 180</description>
        <time_frame>Baseline to 180 days</time_frame>
        <population>All randomized subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Increasing dose from 0.6mg, 1.2mg to 1.8mg subcutaneous daily.
Liraglutide: Active Drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo dose increasing from 0.6mg, 1.2mg to 1.8 mg subcutaneous daily.
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Left Ventricular Ejection Fraction</title>
          <description>Change in left ventricular ejection fraction from baseline to day 180</description>
          <population>All randomized subjects.</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.07" spread="9.1"/>
                    <measurement group_id="O2" value="1.37" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9535</p_value>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Medial Filling Pressure</title>
        <description>Change in medial filling pressure baseline to day 180.</description>
        <time_frame>Baseline to 180 days</time_frame>
        <population>All randomized subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Increasing dose from 0.6mg, 1.2mg to 1.8mg subcutaneous daily.
Liraglutide: Active Drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo dose increasing from 0.6mg, 1.2mg to 1.8 mg subcutaneous daily.
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Medial Filling Pressure</title>
          <description>Change in medial filling pressure baseline to day 180.</description>
          <population>All randomized subjects.</population>
          <units>m/sec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.12" spread="18.8"/>
                    <measurement group_id="O2" value="0.25" spread="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8548</p_value>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Lateral Filling Pressure</title>
        <description>Change in lateral filling pressure baseline to day 180.</description>
        <time_frame>Baseline to 180 days</time_frame>
        <population>All randomized subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Increasing dose from 0.6mg, 1.2mg to 1.8mg subcutaneous daily.
Liraglutide: Active Drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo dose increasing from 0.6mg, 1.2mg to 1.8 mg subcutaneous daily.
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Lateral Filling Pressure</title>
          <description>Change in lateral filling pressure baseline to day 180.</description>
          <population>All randomized subjects.</population>
          <units>m/sec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="12.3"/>
                    <measurement group_id="O2" value="0.39" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4266</p_value>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in 6 Minute Walk Distance</title>
        <description>Change in 6 minute walk distance baseline to day 30</description>
        <time_frame>Baseline to day 30</time_frame>
        <population>All randomized subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Increasing dose from 0.6mg, 1.2mg to 1.8mg subcutaneous daily.
Liraglutide: Active Drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo dose increasing from 0.6mg, 1.2mg to 1.8 mg subcutaneous daily.
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in 6 Minute Walk Distance</title>
          <description>Change in 6 minute walk distance baseline to day 30</description>
          <population>All randomized subjects.</population>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.4" spread="110.8"/>
                    <measurement group_id="O2" value="37.3" spread="99.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1705</p_value>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in 6 Minute Walk Distance</title>
        <description>Change in 6 minute walk distance baseline to 90 days.</description>
        <time_frame>Baseline to 90 days</time_frame>
        <population>All randomized subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Increasing dose from 0.6mg, 1.2mg to 1.8mg subcutaneous daily.
Liraglutide: Active Drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo dose increasing from 0.6mg, 1.2mg to 1.8 mg subcutaneous daily.
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in 6 Minute Walk Distance</title>
          <description>Change in 6 minute walk distance baseline to 90 days.</description>
          <population>All randomized subjects.</population>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.8" spread="132.7"/>
                    <measurement group_id="O2" value="38.7" spread="115.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1309</p_value>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in 6 Minute Walk Distance</title>
        <description>Change in 6 minute walk distance baseline to 180 days.</description>
        <time_frame>Baseline to 180 days</time_frame>
        <population>All randomized subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Increasing dose from 0.6mg, 1.2mg to 1.8mg subcutaneous daily.
Liraglutide: Active Drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo dose increasing from 0.6mg, 1.2mg to 1.8 mg subcutaneous daily.
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in 6 Minute Walk Distance</title>
          <description>Change in 6 minute walk distance baseline to 180 days.</description>
          <population>All randomized subjects.</population>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.7" spread="133.9"/>
                    <measurement group_id="O2" value="55.3" spread="127.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7920</p_value>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Clinical Summary Score Using the Kansas City Cardiomyopathy Questionnaire (KCCQ)</title>
        <description>Change in clinical summary score using the Kansas City Cardiomyopathy Questionnaire (KCCQ) baseline to 30 days. The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life.In the KCCQ, an overall summary score can be derived from the physical function, symptom (frequency and severity), social function and quality of life domains. For each domain, the validity, reproducibility, responsiveness and interpretability have been independently established. Each question is answered by the subject on a 6 point scale (Extremely limited, quite a bit limited, moderately limited, slightly limited, not at all limited, Limited for other reasons or did not do this activity).Scores are transformed to a range of 0-100, in which higher scores reflect better health status.</description>
        <time_frame>Baseline to 30 days</time_frame>
        <population>All randomized subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Increasing dose from 0.6mg, 1.2mg to 1.8mg subcutaneous daily.
Liraglutide: Active Drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo dose increasing from 0.6mg, 1.2mg to 1.8 mg subcutaneous daily.
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Clinical Summary Score Using the Kansas City Cardiomyopathy Questionnaire (KCCQ)</title>
          <description>Change in clinical summary score using the Kansas City Cardiomyopathy Questionnaire (KCCQ) baseline to 30 days. The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life.In the KCCQ, an overall summary score can be derived from the physical function, symptom (frequency and severity), social function and quality of life domains. For each domain, the validity, reproducibility, responsiveness and interpretability have been independently established. Each question is answered by the subject on a 6 point scale (Extremely limited, quite a bit limited, moderately limited, slightly limited, not at all limited, Limited for other reasons or did not do this activity).Scores are transformed to a range of 0-100, in which higher scores reflect better health status.</description>
          <population>All randomized subjects.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.69" spread="25.90"/>
                    <measurement group_id="O2" value="14.44" spread="22.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7026</p_value>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Clinical Summary Score Using the Kansas City Cardiomyopathy Questionnaire (KCCQ)</title>
        <description>Change in clinical summary score using the Kansas City Cardiomyopathy Questionnaire (KCCQ) baseline to 90 days.The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life.In the KCCQ, an overall summary score can be derived from the physical function, symptom (frequency and severity), social function and quality of life domains. For each domain, the validity, reproducibility, responsiveness and interpretability have been independently established. Each question is answered by the subject on a 6 point scale (Extremely limited, quite a bit limited, moderately limited, slightly limited, not at all limited, Limited for other reasons or did not do this activity).Scores are transformed to a range of 0-100, in which higher scores reflect better health status.</description>
        <time_frame>Baseline to 90 days</time_frame>
        <population>All randomized subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Increasing dose from 0.6mg, 1.2mg to 1.8mg subcutaneous daily.
Liraglutide: Active Drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo dose increasing from 0.6mg, 1.2mg to 1.8 mg subcutaneous daily.
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Clinical Summary Score Using the Kansas City Cardiomyopathy Questionnaire (KCCQ)</title>
          <description>Change in clinical summary score using the Kansas City Cardiomyopathy Questionnaire (KCCQ) baseline to 90 days.The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life.In the KCCQ, an overall summary score can be derived from the physical function, symptom (frequency and severity), social function and quality of life domains. For each domain, the validity, reproducibility, responsiveness and interpretability have been independently established. Each question is answered by the subject on a 6 point scale (Extremely limited, quite a bit limited, moderately limited, slightly limited, not at all limited, Limited for other reasons or did not do this activity).Scores are transformed to a range of 0-100, in which higher scores reflect better health status.</description>
          <population>All randomized subjects.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.86" spread="24.99"/>
                    <measurement group_id="O2" value="11.72" spread="23.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2662</p_value>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Clinical Summary Score Using the Kansas City Cardiomyopathy Questionnaire (KCCQ)</title>
        <description>Change in clinical summary score using the Kansas City Cardiomyopathy Questionnaire (KCCQ) from baseline to day 180.The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life.In the KCCQ, an overall summary score can be derived from the physical function, symptom (frequency and severity), social function and quality of life domains. For each domain, the validity, reproducibility, responsiveness and interpretability have been independently established. Each question is answered by the subject on a 6 point scale (Extremely limited, quite a bit limited, moderately limited, slightly limited, not at all limited, Limited for other reasons or did not do this activity).Scores are transformed to a range of 0-100, in which higher scores reflect better health status.</description>
        <time_frame>Baseline to day 180</time_frame>
        <population>All randomized subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Increasing dose from 0.6mg, 1.2mg to 1.8mg subcutaneous daily.
Liraglutide: Active Drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo dose increasing from 0.6mg, 1.2mg to 1.8 mg subcutaneous daily.
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Clinical Summary Score Using the Kansas City Cardiomyopathy Questionnaire (KCCQ)</title>
          <description>Change in clinical summary score using the Kansas City Cardiomyopathy Questionnaire (KCCQ) from baseline to day 180.The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life.In the KCCQ, an overall summary score can be derived from the physical function, symptom (frequency and severity), social function and quality of life domains. For each domain, the validity, reproducibility, responsiveness and interpretability have been independently established. Each question is answered by the subject on a 6 point scale (Extremely limited, quite a bit limited, moderately limited, slightly limited, not at all limited, Limited for other reasons or did not do this activity).Scores are transformed to a range of 0-100, in which higher scores reflect better health status.</description>
          <population>All randomized subjects.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.79" spread="23.83"/>
                    <measurement group_id="O2" value="13.14" spread="23.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6395</p_value>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) Overall Summary Score</title>
        <description>Kansas City Cardiomyopathy Questionnaire (KCCQ) change in overall summary score baseline to 30 days.The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life.In the KCCQ, an overall summary score can be derived from the physical function, symptom (frequency and severity), social function and quality of life domains. For each domain, the validity, reproducibility, responsiveness and interpretability have been independently established. Each question is answered by the subject on a 6 point scale (Extremely limited, quite a bit limited, moderately limited, slightly limited, not at all limited, Limited for other reasons or did not do this activity).Scores are transformed to a range of 0-100, in which higher scores reflect better health status.</description>
        <time_frame>Baseline to 30 days</time_frame>
        <population>All randomized subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Increasing dose from 0.6mg, 1.2mg to 1.8mg subcutaneous daily.
Liraglutide: Active Drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo dose increasing from 0.6mg, 1.2mg to 1.8 mg subcutaneous daily.
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) Overall Summary Score</title>
          <description>Kansas City Cardiomyopathy Questionnaire (KCCQ) change in overall summary score baseline to 30 days.The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life.In the KCCQ, an overall summary score can be derived from the physical function, symptom (frequency and severity), social function and quality of life domains. For each domain, the validity, reproducibility, responsiveness and interpretability have been independently established. Each question is answered by the subject on a 6 point scale (Extremely limited, quite a bit limited, moderately limited, slightly limited, not at all limited, Limited for other reasons or did not do this activity).Scores are transformed to a range of 0-100, in which higher scores reflect better health status.</description>
          <population>All randomized subjects.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.98" spread="23.82"/>
                    <measurement group_id="O2" value="14.01" spread="20.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8218</p_value>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) Overall Summary Score</title>
        <description>Kansas City Cardiomyopathy Questionnaire (KCCQ) change in overall summary score baseline to 90 days.The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life.In the KCCQ, an overall summary score can be derived from the physical function, symptom (frequency and severity), social function and quality of life domains. For each domain, the validity, reproducibility, responsiveness and interpretability have been independently established. Each question is answered by the subject on a 6 point scale (Extremely limited, quite a bit limited, moderately limited, slightly limited, not at all limited, Limited for other reasons or did not do this activity).Scores are transformed to a range of 0-100, in which higher scores reflect better health status.</description>
        <time_frame>Baseline to 90 days</time_frame>
        <population>All randomized subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Increasing dose from 0.6mg, 1.2mg to 1.8mg subcutaneous daily.
Liraglutide: Active Drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo dose increasing from 0.6mg, 1.2mg to 1.8 mg subcutaneous daily.
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) Overall Summary Score</title>
          <description>Kansas City Cardiomyopathy Questionnaire (KCCQ) change in overall summary score baseline to 90 days.The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life.In the KCCQ, an overall summary score can be derived from the physical function, symptom (frequency and severity), social function and quality of life domains. For each domain, the validity, reproducibility, responsiveness and interpretability have been independently established. Each question is answered by the subject on a 6 point scale (Extremely limited, quite a bit limited, moderately limited, slightly limited, not at all limited, Limited for other reasons or did not do this activity).Scores are transformed to a range of 0-100, in which higher scores reflect better health status.</description>
          <population>All randomized subjects.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.17" spread="24.46"/>
                    <measurement group_id="O2" value="10.62" spread="22.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1124</p_value>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) Overall Summary Score.</title>
        <description>Kansas City Cardiomyopathy Questionnaire (KCCQ) change in overall summary score baseline to 180 days.The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life.In the KCCQ, an overall summary score can be derived from the physical function, symptom (frequency and severity), social function and quality of life domains. For each domain, the validity, reproducibility, responsiveness and interpretability have been independently established. Each question is answered by the subject on a 6 point scale (Extremely limited, quite a bit limited, moderately limited, slightly limited, not at all limited, Limited for other reasons or did not do this activity).Scores are transformed to a range of 0-100, in which higher scores reflect better health status.</description>
        <time_frame>Baseline to 180 days</time_frame>
        <population>All randomized subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Increasing dose from 0.6mg, 1.2mg to 1.8mg subcutaneous daily.
Liraglutide: Active Drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo dose increasing from 0.6mg, 1.2mg to 1.8 mg subcutaneous daily.
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) Overall Summary Score.</title>
          <description>Kansas City Cardiomyopathy Questionnaire (KCCQ) change in overall summary score baseline to 180 days.The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life.In the KCCQ, an overall summary score can be derived from the physical function, symptom (frequency and severity), social function and quality of life domains. For each domain, the validity, reproducibility, responsiveness and interpretability have been independently established. Each question is answered by the subject on a 6 point scale (Extremely limited, quite a bit limited, moderately limited, slightly limited, not at all limited, Limited for other reasons or did not do this activity).Scores are transformed to a range of 0-100, in which higher scores reflect better health status.</description>
          <population>All randomized subjects.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.44" spread="22.61"/>
                    <measurement group_id="O2" value="13.25" spread="22.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8088</p_value>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Individual Component of the Primary Endpoint- Mortality</title>
        <description>Individual component of the primary endpoint of mortality at 180 days after randomization</description>
        <time_frame>Randomization to 180 days</time_frame>
        <population>All randomized subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Increasing dose from 0.6mg, 1.2mg to 1.8mg subcutaneous daily.
Liraglutide: Active Drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo dose increasing from 0.6mg, 1.2mg to 1.8 mg subcutaneous daily.
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Individual Component of the Primary Endpoint- Mortality</title>
          <description>Individual component of the primary endpoint of mortality at 180 days after randomization</description>
          <population>All randomized subjects.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7764</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Individual Component of the Primary Endpoint- Heart Failure Hospitalization</title>
        <description>Individual component of the primary endpoint- Heart Failure hospitalization from randomization to 180 days</description>
        <time_frame>Randomization to 180 days</time_frame>
        <population>All randomized subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Increasing dose from 0.6mg, 1.2mg to 1.8mg subcutaneous daily.
Liraglutide: Active Drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo dose increasing from 0.6mg, 1.2mg to 1.8 mg subcutaneous daily.
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Individual Component of the Primary Endpoint- Heart Failure Hospitalization</title>
          <description>Individual component of the primary endpoint- Heart Failure hospitalization from randomization to 180 days</description>
          <population>All randomized subjects.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1701</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Individual Component of the Primary Endpoint- Time-averaged Proportional Change in NT-proBNP</title>
        <description>Individual component of the primary endpoint- time-averaged proportional change in NT-proBNP from baseline to 180 days</description>
        <time_frame>Baseline to 180 days</time_frame>
        <population>All randomized subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Increasing dose from 0.6mg, 1.2mg to 1.8mg subcutaneous daily.
Liraglutide: Active Drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo dose increasing from 0.6mg, 1.2mg to 1.8 mg subcutaneous daily.
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Individual Component of the Primary Endpoint- Time-averaged Proportional Change in NT-proBNP</title>
          <description>Individual component of the primary endpoint- time-averaged proportional change in NT-proBNP from baseline to 180 days</description>
          <population>All randomized subjects.</population>
          <units>weighted average of ratio to baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="335.81" spread="445.8"/>
                    <measurement group_id="O2" value="317" spread="307.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6532</p_value>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Global Ranking of Predefined Events</title>
        <description>A rank score based on time to death, time to adjudicated heart failure hospitalization, time to emergency department visit and time-averaged proportional change in NTproBNP through d180. See Outcome Measure 1 for a general description of the outcome derivation.</description>
        <time_frame>Baseline to 180 days</time_frame>
        <population>All randomized subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Increasing dose from 0.6mg, 1.2mg to 1.8mg subcutaneous daily.
Liraglutide: Active Drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo dose increasing from 0.6mg, 1.2mg to 1.8 mg subcutaneous daily.
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Global Ranking of Predefined Events</title>
          <description>A rank score based on time to death, time to adjudicated heart failure hospitalization, time to emergency department visit and time-averaged proportional change in NTproBNP through d180. See Outcome Measure 1 for a general description of the outcome derivation.</description>
          <population>All randomized subjects.</population>
          <units>rank</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144.29" spread="87.63"/>
                    <measurement group_id="O2" value="157.05" spread="85.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2033</p_value>
            <method>Rank score</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline to day 210.</time_frame>
      <desc>All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.</desc>
      <group_list>
        <group group_id="E1">
          <title>Liraglutide</title>
          <description>Increasing dose from 0.6mg, 1.2mg to 1.8mg subcutaneous (SQ) daily.
Liraglutide: Active Drug</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo dose increasing from 0.6mg, 1.2mg to 1.8 mg subcutaneous (SQ) daily.
Placebo: Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointentinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="154"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Viral Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>International Normalised Ratio Increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="154"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Hyperolmolar Hyperglycaemic State</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate Cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic Encephalopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic unconsciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="146"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="146"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Adrian Hernandez, MD</name_or_title>
      <organization>Duke Clinical Research Institute</organization>
      <phone>919-668-7515</phone>
      <email>adrian.hernandez@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

